D
aTyr Pharma, Inc.
ATYR
$3.99
$0.4412.39%
D
Sell
10/18/2024Upgraded
aTyr Pharma, Inc. (ATYR) was upgraded to D- from E+ on 10/18/2024 due to an increase in the total return index and volatility index.
aTyr Pharma, Inc. (ATYR) was upgraded to D- from E+ on 10/18/2024 due to an increase in the total return index and volatility index.
E
Sell
10/3/2024Downgrade
aTyr Pharma, Inc. (ATYR) was downgraded to E+ from D- on 10/3/2024 due to a decline in the volatility index and total return index.
aTyr Pharma, Inc. (ATYR) was downgraded to E+ from D- on 10/3/2024 due to a decline in the volatility index and total return index.
D
Sell
9/18/2024Upgraded
aTyr Pharma, Inc. (ATYR) was upgraded to D- from E+ on 9/18/2024 due to an increase in the volatility index and total return index.
aTyr Pharma, Inc. (ATYR) was upgraded to D- from E+ on 9/18/2024 due to an increase in the volatility index and total return index.
E
Sell
9/3/2024Downgrade
aTyr Pharma, Inc. (ATYR) was downgraded to E+ from D- on 9/3/2024 due to a decline in the volatility index.
aTyr Pharma, Inc. (ATYR) was downgraded to E+ from D- on 9/3/2024 due to a decline in the volatility index.
D
Sell
8/16/2024Upgraded
aTyr Pharma, Inc. (ATYR) was upgraded to D- from E+ on 8/16/2024 due to an increase in the volatility index and total return index.
aTyr Pharma, Inc. (ATYR) was upgraded to D- from E+ on 8/16/2024 due to an increase in the volatility index and total return index.
E
Sell
7/24/2024Downgrade
aTyr Pharma, Inc. (ATYR) was downgraded to E+ from D- on 7/24/2024 due to a decline in the volatility index and total return index.
aTyr Pharma, Inc. (ATYR) was downgraded to E+ from D- on 7/24/2024 due to a decline in the volatility index and total return index.
D
Sell
6/26/2024Upgraded
aTyr Pharma, Inc. (ATYR) was upgraded to D- from E+ on 6/26/2024 due to an increase in the volatility index.
aTyr Pharma, Inc. (ATYR) was upgraded to D- from E+ on 6/26/2024 due to an increase in the volatility index.
E
Sell
6/10/2024Downgrade
aTyr Pharma, Inc. (ATYR) was downgraded to E+ from D- on 6/10/2024 due to a decline in the volatility index and total return index.
aTyr Pharma, Inc. (ATYR) was downgraded to E+ from D- on 6/10/2024 due to a decline in the volatility index and total return index.
D
Sell
5/20/2024Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 5/20/2024 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2491 to -$0.2344.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 5/20/2024 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2491 to -$0.2344.
E
Sell
5/3/2024Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index, total return index and growth index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
4/11/2024Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 4/11/2024 due to an increase in the volatility index and total return index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 4/11/2024 due to an increase in the volatility index and total return index.
E
Sell
3/21/2024Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 3/21/2024 due to a decline in the growth index, volatility index and solvency index. Total revenue declined 100% from $353 to $0, earnings per share declined from -$0.1959 to -$0.2488, and EBIT declined 26.51% from -$12.62M to -$15.96M.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 3/21/2024 due to a decline in the growth index, volatility index and solvency index. Total revenue declined 100% from $353 to $0, earnings per share declined from -$0.1959 to -$0.2488, and EBIT declined 26.51% from -$12.62M to -$15.96M.
D
Sell
3/1/2024Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 3/1/2024 due to an increase in the volatility index and total return index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 3/1/2024 due to an increase in the volatility index and total return index.
E
Sell
2/14/2024Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 2/14/2024 due to a decline in the volatility index and growth index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 2/14/2024 due to a decline in the volatility index and growth index.
D
Sell
1/25/2024Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index.
E
Sell
1/9/2024Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index and total return index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index and total return index.
D
Sell
12/19/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 12/19/2023 due to an increase in the volatility index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 12/19/2023 due to an increase in the volatility index.
E
Sell
12/1/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 12/1/2023 due to a decline in the volatility index and total return index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 12/1/2023 due to a decline in the volatility index and total return index.
D
Sell
11/14/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 11/14/2023 due to an increase in the growth index and volatility index. Operating cash flow increased 20.41% from -$12.01M to -$9.56M, earnings per share increased from -$0.2237 to -$0.1959, and EBIT increased 6.96% from -$13.56M to -$12.62M.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 11/14/2023 due to an increase in the growth index and volatility index. Operating cash flow increased 20.41% from -$12.01M to -$9.56M, earnings per share increased from -$0.2237 to -$0.1959, and EBIT increased 6.96% from -$13.56M to -$12.62M.
E
Sell
11/9/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 11/9/2023 due to a decline in the volatility index, growth index and total return index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 11/9/2023 due to a decline in the volatility index, growth index and total return index.
D
Sell
10/23/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 10/23/2023 due to an increase in the volatility index, total return index and valuation index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 10/23/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
10/5/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 10/5/2023 due to a decline in the volatility index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 10/5/2023 due to a decline in the volatility index.
D
Sell
9/19/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 9/19/2023 due to an increase in the volatility index and total return index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 9/19/2023 due to an increase in the volatility index and total return index.
E
Sell
8/30/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index.
D
Sell
8/14/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 8/14/2023 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2852 to -$0.2237.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 8/14/2023 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2852 to -$0.2237.
E
Sell
8/2/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 8/2/2023 due to a decline in the volatility index and growth index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 8/2/2023 due to a decline in the volatility index and growth index.
D
Sell
7/17/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 7/17/2023 due to an increase in the volatility index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 7/17/2023 due to an increase in the volatility index.
E
Sell
6/27/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 6/27/2023 due to a decline in the volatility index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 6/27/2023 due to a decline in the volatility index.
D
Sell
6/8/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 6/8/2023 due to an increase in the volatility index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 6/8/2023 due to an increase in the volatility index.
E
Sell
5/19/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 5/19/2023 due to a decline in the growth index, volatility index and total return index. EBIT declined 60.84% from -$7.95M to -$12.79M, and earnings per share declined from -$0.2629 to -$0.2852.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 5/19/2023 due to a decline in the growth index, volatility index and total return index. EBIT declined 60.84% from -$7.95M to -$12.79M, and earnings per share declined from -$0.2629 to -$0.2852.
D
Sell
5/10/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 5/10/2023 due to an increase in the volatility index and growth index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 5/10/2023 due to an increase in the volatility index and growth index.
E
Sell
4/21/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index and total return index.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index and total return index.
D
Sell
4/4/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 4/4/2023 due to an increase in the volatility index.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 4/4/2023 due to an increase in the volatility index.
E
Sell
3/16/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 6.98 to 5.62.
aTyr Pharma, Inc. (LIFE) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 6.98 to 5.62.
D
Sell
3/14/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/27/2023Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D from D- on 2/27/2023 due to an increase in the volatility index.
aTyr Pharma, Inc. (LIFE) was upgraded to D from D- on 2/27/2023 due to an increase in the volatility index.
D
Sell
2/8/2023Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index, solvency index and volatility index. The quick ratio declined from 9.61 to 6.98.
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index, solvency index and volatility index. The quick ratio declined from 9.61 to 6.98.
D
Sell
5/31/2022Upgraded
aTyr Pharma, Inc. (ATYR) was upgraded to D from D- on 05/31/2022.
aTyr Pharma, Inc. (ATYR) was upgraded to D from D- on 05/31/2022.
D
Sell
5/13/2022Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, volatility index and solvency index. EBIT declined 43.26% from -$8.64M to -$12.38M, earnings per share declined from -$0.308 to -$0.4369, and operating cash flow declined 25.14% from -$8.09M to -$10.12M.
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, volatility index and solvency index. EBIT declined 43.26% from -$8.64M to -$12.38M, earnings per share declined from -$0.308 to -$0.4369, and operating cash flow declined 25.14% from -$8.09M to -$10.12M.
D
Sell
5/5/2022Upgraded
aTyr Pharma, Inc. (ATYR) was upgraded to D from D- on 05/05/2022.
aTyr Pharma, Inc. (ATYR) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 4/20/2022 due to a decline in the volatility index.
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 4/20/2022 due to a decline in the volatility index.
D
Sell
4/18/2022Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to D from D+ on 4/18/2022 due to a large decline in the total return index and volatility index.
aTyr Pharma, Inc. (LIFE) was downgraded to D from D+ on 4/18/2022 due to a large decline in the total return index and volatility index.
D
Sell
11/9/2021Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D+ from D- on 11/9/2021 due to an increase in the total return index.
aTyr Pharma, Inc. (LIFE) was upgraded to D+ from D- on 11/9/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
aTyr Pharma, Inc. (ATYR) was downgraded to D- from D+ on 11/08/2021.
aTyr Pharma, Inc. (ATYR) was downgraded to D- from D+ on 11/08/2021.
D
Sell
10/19/2021Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D+ from D on 10/19/2021 due to an increase in the total return index, valuation index and volatility index.
aTyr Pharma, Inc. (LIFE) was upgraded to D+ from D on 10/19/2021 due to an increase in the total return index, valuation index and volatility index.
D
Sell
10/4/2021Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to D from D+ on 10/4/2021 due to a decline in the valuation index.
aTyr Pharma, Inc. (LIFE) was downgraded to D from D+ on 10/4/2021 due to a decline in the valuation index.
D
Sell
9/17/2021Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D+ from D on 9/17/2021 due to a substantial increase in the total return index and volatility index.
aTyr Pharma, Inc. (LIFE) was upgraded to D+ from D on 9/17/2021 due to a substantial increase in the total return index and volatility index.
D
Sell
11/19/2020Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D from D- on 11/19/2020 due to a significant increase in the growth index and total return index. Operating cash flow increased 13.24% from -$6.4M to -$5.56M, and earnings per share increased from -$0.6889 to -$0.6839.
aTyr Pharma, Inc. (LIFE) was upgraded to D from D- on 11/19/2020 due to a significant increase in the growth index and total return index. Operating cash flow increased 13.24% from -$6.4M to -$5.56M, and earnings per share increased from -$0.6889 to -$0.6839.
D
Sell
8/14/2020Downgrade
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 8/14/2020 due to a significant decline in the growth index. EBIT declined 439.86% from $1.86M to -$6.32M, operating cash flow declined 411.13% from $2.06M to -$6.4M, and earnings per share declined from $0.25 to -$0.69.
aTyr Pharma, Inc. (LIFE) was downgraded to D- from D on 8/14/2020 due to a significant decline in the growth index. EBIT declined 439.86% from $1.86M to -$6.32M, operating cash flow declined 411.13% from $2.06M to -$6.4M, and earnings per share declined from $0.25 to -$0.69.
D
Sell
5/1/2020Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index, volatility index and total return index.
aTyr Pharma, Inc. (LIFE) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index, volatility index and total return index.
D
Sell
3/7/2017Upgraded
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 3/7/2017 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.6498 to -$0.5832, and EBIT increased 10.16% from -$15.43M to -$13.87M.
aTyr Pharma, Inc. (LIFE) was upgraded to D- from E+ on 3/7/2017 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.6498 to -$0.5832, and EBIT increased 10.16% from -$15.43M to -$13.87M.
E
Sell
9/28/2016Downgrade
aTyr Pharma Inc. (LIFE) was downgraded to E+ from D- on 9/28/2016 due to a decline in the volatility index and valuation index.
aTyr Pharma Inc. (LIFE) was downgraded to E+ from D- on 9/28/2016 due to a decline in the volatility index and valuation index.
D
Sell
9/12/2016Upgraded
aTyr Pharma Inc. (LIFE) was upgraded to D- from E+ on 9/12/2016 due to an increase in the volatility index and valuation index.
aTyr Pharma Inc. (LIFE) was upgraded to D- from E+ on 9/12/2016 due to an increase in the volatility index and valuation index.
E
Sell
8/26/2016Downgrade
aTyr Pharma Inc. (LIFE) was downgraded to E+ from D- on 8/26/2016 due to a decline in the volatility index.
aTyr Pharma Inc. (LIFE) was downgraded to E+ from D- on 8/26/2016 due to a decline in the volatility index.
D
Sell
8/11/2016Upgraded
aTyr Pharma Inc. (LIFE) was upgraded to D- from E+ on 8/11/2016 due to a major increase in the growth index and efficiency index. Earnings per share increased from -$0.6808 to -$0.65, net income increased 4.38% from -$16.09M to -$15.38M, and EBIT increased 4.23% from -$16.12M to -$15.43M.
aTyr Pharma Inc. (LIFE) was upgraded to D- from E+ on 8/11/2016 due to a major increase in the growth index and efficiency index. Earnings per share increased from -$0.6808 to -$0.65, net income increased 4.38% from -$16.09M to -$15.38M, and EBIT increased 4.23% from -$16.12M to -$15.43M.
E
Sell
4/1/2016Downgrade
aTyr Pharma Inc. (LIFE) was downgraded to E+ from D- on 4/1/2016 due to a major decline in the growth index, volatility index and total return index. EBIT declined 45.7% from -$11.31M to -$16.48M, earnings per share declined from -$0.4804 to -$0.6987, and operating cash flow declined 3.89% from -$9.47M to -$9.84M.
aTyr Pharma Inc. (LIFE) was downgraded to E+ from D- on 4/1/2016 due to a major decline in the growth index, volatility index and total return index. EBIT declined 45.7% from -$11.31M to -$16.48M, earnings per share declined from -$0.4804 to -$0.6987, and operating cash flow declined 3.89% from -$9.47M to -$9.84M.
D
Sell
2/1/2016Upgraded
aTyr Pharma Inc. (LIFE) was upgraded to D- from E+ on 2/1/2016 due to an increase in the growth index and valuation index. EBIT increased 3.81% from -$10.9M to -$11.31M.
aTyr Pharma Inc. (LIFE) was upgraded to D- from E+ on 2/1/2016 due to an increase in the growth index and valuation index. EBIT increased 3.81% from -$10.9M to -$11.31M.
E
Sell
11/2/2015Upgraded
aTyr Pharma Inc. (LIFE) was upgraded to E+ from E on 11/2/2015 due to a large increase in the growth index, solvency index and total return index. Debt to equity declined from -0.1 to 0.05, the quick ratio increased from 4.72 to 10.99, and operating cash flow increased 78.32% from -$6.29M to -$11.21M.
aTyr Pharma Inc. (LIFE) was upgraded to E+ from E on 11/2/2015 due to a large increase in the growth index, solvency index and total return index. Debt to equity declined from -0.1 to 0.05, the quick ratio increased from 4.72 to 10.99, and operating cash flow increased 78.32% from -$6.29M to -$11.21M.
E
Sell
8/3/2015None
aTyr Pharma, Inc. (ATYR) was downgraded to E from U on 08/03/2015.
aTyr Pharma, Inc. (ATYR) was downgraded to E from U on 08/03/2015.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
